This week Mary and Alex speak with Cliff Reed, Founding CEO, and Dennis Watson, VP Business Development, of Travera, a company specializing in new technology enhancing the landscape of late stage cancer treatment.

Listen on our website, www.downthereaware.com/podcast, or wherever you get your podcasts.

#Podcast #Spotify #Anchor #research #advocacy #cancer #Travera #genomics #DNA #MIT #FDA #CLIA #LDT #cancerresearch #technology #cancertechnology #innovation #groundbreaking #latestagecancer #stage4cancer #uterinecancer #ovariancancer #leukemia

Stay Connected 

Email Us: downthereaware@gmail.com

Instagram:@downthereaware 

Facebook: Down There Aware 

Twitter: @downthereaware

Pinterest: Down There Aware

TikTok: Down There Aware

Episode Links

TRAVERA

Episode Highlights

• Intro [0:13 ]

  
  



• Welcome Back! [1:25 ]

  
  



• Guest introductions [1:44 ]

  
  



• M.I.T. technology [3:42 ]

  
  



• Genomics and DNA sequencing [3:58 ]

  
  



• Limited patients [4:05 ]

  
  



• New measurement tool [4:48 ]

  
  



• MIT/Dana Farber Cancer Institute partnership [5:32 ]

  
  



• Infectious disease comparison [5:48 ]

  
  



• Multiple Myeloma [6:38 ]

  
  



• “Cheat code” [7:30 ]

  
  



• Commercial launch [9:09 ]

  
  



• Test offered for free [10:15 ]

  
  



• Working with physicians [10:55 ]

  
  



• Trial and error process for patient [13:20 ]

  
  



• Advocacy groups [15:25 ]

  
  



• Patient profile [16:01 ]

  
  



• Cancer mutation [17:57 ]

  
  



• Access to live cancer cells [18:38 ]

  
  



• Quick turn-around for results[21:30 ]

  
  



• No additional burden on patient [23:35 ]

  
  



• Early stage testing and limited data [24:28 ]

  
  



• Predictive accuracy over 80% [25:12 ]

  
  



• Late stage cancer patients [26:25 ]

  
  



• Response from oncology community [28:00 ]

  
  



• Difference in this x vivo test [29:25 }

  
  



• No financial risk [30:00 ]

  
  



• Great value to research and future patients [31:57 ]

  
  



• MIT intent [34:57 ]

  
  



• Great creative minds in scientific research [36:15 ]

  
  



• Future of Travera’s efforts [36:55 ]

  
  



• The bigger plan [39:01 ]

  
  



• FDA approval/CLIA certification [40:05 ]

  
  



• Laboratory Developed Test (LDT) [40:21 ]

  
  



• Potential to greatly benefit newly diagnosed patients[41:49 ]

  
  



• Microchip specs [43:45 ]

  
  



• Physics vs biochemistry[46:20 ]

  
  



• Simple comparison to a diving board [47:05 ]

  
  



• Speed and logic [49:47 ]

  
  



• If someone is listening today and is interested [51:30 ]

  
  



• dwatson@travera.com [52:23 ]

  
  



• PHI and HIPAA [53:35 ]

  
  



• Hearing from those who know best [55:03 ]

  
  

• Thanks for listening! [56:19 ]

  
  

Stay Connected 

Podcast, Spotify, Anchor, research, advocacy, cancer, Travera, genomics, DNA, MIT, FDA, CLIA, LDT, cancer research, technology, cancer technology, innovation, groundbreaking, late-stage cancer, stage 4 cancer, uterine cancer, ovarian cancer, leukemia